Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug119 | AV-COVID-19 Wiki | 0.58 |
drug3574 | VPM1002 Wiki | 0.58 |
drug2490 | Placebo Wiki | 0.13 |
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.41 |
D007239 | Infection NIH | 0.24 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
This is an adaptive Phase I trial of a vaccine consisting of autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein, with or without GM-CSF, to prevent COVID-19 in adults.
Description: Percentage of participants with solicited AEs (local, systemic) for 7 days following vaccination by severity score, duration, and peak intensity.
Measure: Frequency of solicited local and systemic reactogenicity adverse events (AEs) Time: until follow up day 7Description: Safety laboratory values (Serum Chemistry) by FDA toxicity scoring (absolute and change from baseline where identified) at 7 days after each vaccination.
Measure: Safety Laboratory Values (Serum Chemistry) Time: until follow up day 7Description: Safety laboratory values (Hematology) by FDA toxicity scoring (absolute and change from baseline where identified) at 7 days after each vaccination.
Measure: Safety Laboratory Values (Hematology) Time: until follow up day 7Description: Percentage of participants with serious undesirable effect associated with the use of a medical product in a patient, which consist of death, life-threatening, hospitalization, disability or permanent damage, congenital anomaly/birth defect, required intervention to prevent permanent impairment or damage (devices), dan other serious important medical events
Measure: Frequency of any serious adverse events (SAEs) Time: until follow up day 365Description: NOCMCs will be documented from the time of study vaccination through approximately 1 year after study vaccination
Measure: Frequency of any new-onset chronic medical conditions (NOCMCs) Time: until follow up day 365Description: Percentage of participants with MAAEs, defined as AEs that lead to an unscheduled visit to a healthcare practitioner, through Day 365 by MedDRA classification, severity score, and relatedness.
Measure: Frequency of medically attended adverse events (MAAEs) Time: until follow up day 365Description: Percentage of participants with unsolicited AEs (eg, treatment-emergent, serious, suspected unexpected serious, those of special interest, all MAAEs) or AESIs (potential immune-mediated medical conditions or AEs relevant to COVID-19) through the first 90 days by MedDRA classification, severity score, and relatedness.
Measure: Frequency of Unsolicited AE and Adverse Events of Special Interest (AESIs) Time: until follow up day 90Description: Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMFRs through Day 28.
Measure: Serum IgG Antibody Levels Expressed as Geometric Mean Fold Rises (GMFRs) Time: until follow up day 28Description: Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by enzyme-linked immunosorbent assay (ELISA) expressed as GMTs through Day 28.
Measure: Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs) Time: until follow up day 28Description: Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as SCRs through Day 28. SCR is the proportion of participants with ≥4-fold rises in ELISA units.
Measure: Serum IgG Antibody Levels Expressed as Seroconversion Rates (SCRs) Time: until follow up day 28Description: Neutralizing antibody activity as detected by microneutralization assay (MN) expressed as GMTs at multiple time points through Day 28.
Measure: Neutralizing Antibody Activity Expressed as GMTs Time: until follow up day 28Description: Neutralizing antibody activity as detected by MN expressed as GMFRs at multiple time points through Day 28.
Measure: Neutralizing Antibody Activity Expressed as GMFRs Time: until follow up day 28Description: Neutralizing antibody activity as detected by MN expressed as SCRs at multiple time points through Day 28.
Measure: Neutralizing Antibody Activity Expressed as SCRs Time: until follow up day 28Description: Cell-mediated (Th1/Th2) pathways as measured by whole blood (flow cytometry) and/or in vitro peripheral blood mononuclear cell (PBMC) stimulation (eg, enzyme-linked immunospot [ELISpot], cytokine staining) with SARS-CoV-2 rS protein(s) through Day 28.
Measure: Assessment of Cell-Mediated (T helper 1 [Th1]/T helper 2 [Th2]) Pathways Time: until follow up day 28Description: Measurement of IgG in subject blood after one month
Measure: Optimal dose of SARS-CoV2 antigen and GM-CSF Time: until follow up month oneDescription: Measurement of IgG and neutralizing antibody in subject blood after 12 months
Measure: Duration of detection IgG and neutralizing antibody againts SARS-CoV-2in blood after vaccination Time: until follow up month 12Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports